Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk.
Alzheimer's & Dementia. 2020-10-08; :
Lire sur PubMed
Thomas A(1), Baillet M(1), Proust-Lima C(1), Féart C(1), Foubert-Samier A(1)(2), Helmer C(1), Catheline G(3)(4), Samieri C(1).
(1)INSERM, BPH, U1219, Univ. Bordeaux, Bordeaux, F-33000, France.
(2)Institut des Maladies Neurodégénératives, Bordeaux Univ. Hospital, Bordeaux, F-33000, France.
(3)CNRS, INCIA, UMR5287, Univ. Bordeaux, Bordeaux, F-33000, France.
(4)Laboratoire Neuroimagerie et vie quotidienne, EPHE-PSL, Bordeaux, F-33000, France.
INTRODUCTION: We searched for consistent associations of an omega-3 index in plasma (sum of eicosapentaenoic acid EPA and docosahexaenoic acid DHA) with several dementia-related outcomes in a large cohort of older adults.
METHODS: We included 1279 participants from the Three-City study, non-demented at the time of blood measurements at baseline, with face-to-face neuropsychological assessment and systematic detection of incident dementia over a 17-year follow-up. An ancillary study included 467 participants with up to three repeated brain imaging exams over 10 years.
RESULTS: In multivariable models, higher levels of plasma EPA+DHA were consistently associated with a lower risk of dementia (hazard ratio for 1 standard deviation = 0.87 [95% confidence interval, 0.76-0.98]), and a lower decline in global cognition (P = .04 for change over time), memory (P = .06), and medial temporal lobe volume (P = .02).
DISCUSSION: This prospective study provides compelling evidence for a relationship between long-chain omega-3 fatty acids levels and lower risks for dementia and related outcomes.
© 2020 the Alzheimer’s Association.